

# Changchun Deng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2094429/publications.pdf>

Version: 2024-02-01

38  
papers

1,010  
citations

623734

14  
h-index

434195

31  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1566  
citing authors

#	ARTICLE	IF	CITATIONS
1	Umbralisib, a novel PI3K $\gamma$ and casein kinase-1 $\mu$ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. <i>Lancet Oncology</i> , 2018, 19, 486-496.	10.7	178
2	Brentuximab Vedotin. <i>Clinical Cancer Research</i> , 2013, 19, 22-27.	7.0	134
3	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. <i>Blood</i> , 2018, 131, 397-407.	1.4	109
4	Silencing c-Myc translation as a therapeutic strategy through targeting PI3K $\gamma$ and CK1 $\mu$ in hematological malignancies. <i>Blood</i> , 2017, 129, 88-99.	1.4	92
5	Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. <i>Blood</i> , 2021, 137, 2161-2170.	1.4	88
6	A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. <i>British Journal of Haematology</i> , 2017, 177, 243-253.	2.5	61
7	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 2096-2106.	7.0	48
8	High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 132.	17.0	39
9	Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 219-227.	2.3	31
10	Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 15.	5.0	29
11	Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial. <i>Blood</i> , 2015, 126, 253-253.	1.4	25
12	The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF- $\kappa$ B. <i>Clinical Cancer Research</i> , 2015, 21, 134-145.	7.0	22
13	TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 4154-4154.	1.4	20
14	Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. <i>Leukemia and Lymphoma</i> , 2017, 58, 2548-2557.	1.3	18
15	TGR-1202, a Novel Once Daily PI3K $\gamma$ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1984-1984.	1.4	14
16	Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 757-760.	2.5	13
17	The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience. <i>Blood</i> , 2015, 126, 586-586.	1.4	13
18	New Strategies in the Treatment of Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 3499-3508.	7.0	9

#	ARTICLE	IF	CITATIONS
19	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i> . <i>Haematologica</i> , 2017, 102, e275-e277.	3.5	8
20	Clinical and Biological Evaluation of the Novel CD30/CD16A Tetraivalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). <i>Blood</i> , 2018, 132, 2908-2908.	1.4	8
21	PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses. <i>Blood</i> , 2016, 128, 2999-2999.	1.4	6
22	The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma). <i>Blood</i> , 2014, 124, 4449-4449.	1.4	5
23	ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. <i>Oncotarget</i> , 2020, 11, 3432-3442.	1.8	5
24	Plasmablastic lymphoma in an HIV patient with cutaneous presentation: A case of remarkable remission in a typically refractory disease. <i>JAAD Case Reports</i> , 2020, 6, 161-165.	0.8	4
25	A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K- $\hat{\gamma}$ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies. <i>Blood</i> , 2013, 122, 4373-4373.	1.4	4
26	The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1824-1824.	1.4	4
27	Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin's lymphoma and immunoepigenetic priming.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19012-e19012.	1.6	4
28	A Phase 1-2 Study of Brentuximab Vedotin (Bv) and Bendamustine (B) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , 2014, 124, 3084-3084.	1.4	3
29	Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development. <i>Blood</i> , 2015, 126, 1282-1282.	1.4	3
30	The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8049-8049.	1.6	3
31	Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072094734.	2.5	2
32	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 3014-3017.	1.3	2
33	Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): The pralatrexate/romidepsin doublet.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2552-2552.	1.6	2
34	The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 3703-3703.	1.4	2
35	Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. <i>Blood</i> , 2016, 128, 291-291.	1.4	1
36	Combination Of Selective HDAC Inhibitors That Target Specific HDAC Isoforms Synergistically Inhibits T Cell Lymphoma. <i>Blood</i> , 2013, 122, 5142-5142.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma. Blood, 2014, 124, 1770-1770.	1.4	0
38	Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT. Blood, 2016, 128, 5834-5834.	1.4	0